Mural Oncology PLC - MURA STOCK NEWS

Mural Oncology (MURA) announced key milestones and pipeline updates, with significant catalysts expected throughout 2025. The company reached 75% of overall survival events for its ARTISTRY-7 trial, evaluating nemvaleukin with pembrolizumab in platinum-resistant ovarian cancer, with interim data expected in late Q1/early Q2 2025.

Two new development candidates were nominated: MURA-8518, a novel IL-18 therapy, and MURA-7012, targeting IL-12 pathways. The company plans an IND submission for MURA-8518 in Q4 2025. Additional readouts include ARTISTRY-6 trial data for mucosal melanoma in Q2 2025, and preliminary data for less-frequent intravenous dosing in cutaneous melanoma patients in 1H and 2H 2025.

Through operational efficiencies, Mural has extended its cash runway into Q1 2026, positioning itself to advance through these key upcoming catalysts.

Mural Oncology announced equity grants to four new employees as inducement awards under Nasdaq Rule 5635(c)(4). The grants include 26,300 stock options and 13,200 restricted stock units. The stock options were granted at $4.18 per share, matching Nasdaq's closing price on December 2, 2024.

The options have a ten-year term with a four-year vesting schedule: 25% vests after one year, followed by quarterly vesting of 6.25%. The restricted stock units vest over four years at 25% annually. Both grants are subject to continued employment and the company's 2024 Inducement Stock Option and Incentive Plan.

Mural Oncology has published promising clinical data from its completed ARTISTRY-1 phase 1/2 trial of nemvaleukin, showing positive antitumor activity in both monotherapy and combination therapy with pembrolizumab. The trial, involving 286 patients across 32 sites, demonstrated a 10% overall response rate in monotherapy and 13% in combination therapy. Notable results included a 21% response rate in platinum-resistant ovarian cancer (PROC) patients and 33.3% in mucosal melanoma patients. The treatment was generally well-tolerated with manageable side effects. Data readouts from two ongoing registrational trials are expected in Q1/Q2 2025.

Mural Oncology (NASDAQ: MURA) reported Q3 2024 financial results and pipeline updates. The company completed enrollment in two key trials: ARTISTRY-7 (456 patients) for platinum-resistant ovarian cancer and ARTISTRY-6 Cohort 2 (92 patients) for mucosal melanoma, with data readouts expected in late Q1/early Q2 2025 and Q2 2025, respectively. Financial highlights include cash position of $175.5M, R&D expenses of $27.6M (down from $40.4M in Q3 2023), and net loss of $31.8M (improved from $51.3M in Q3 2023). The company expects its current cash runway to extend into Q4 2025.

Mural Oncology (Nasdaq: MURA), a clinical-stage immuno-oncology company, has announced its participation in two upcoming investor conferences. The company will attend the Jefferies London Healthcare Conference for one-on-one meetings on November 19-20, 2024, and the Piper Sandler 36th Annual Healthcare Conference for a fireside chat on December 9, 2024, at 9:30 a.m. ET. Key management team members participating include CEO Caroline Loew, Chief Medical Officer Vicki Goodman, and CFO Adam Cutler. A webcast of the Piper Sandler presentation will be available on the company's investor relations website.

Mural Oncology presented clinical and preclinical data at the 39th SITC Annual Meeting. The ARTISTRY-3 trial showed that less frequent IV dosing of nemvaleukin demonstrated tumor site-specific immune activation in ovarian cancer and mucosal melanoma patients. Preclinical data from IL-18 variants showed durable immune responses and tumor growth inhibition, with candidate nomination expected by end of 2024 and IND submission in Q4 2025. The company's IL-12 program demonstrated potential to mitigate cytokine toxicity, with candidate nomination planned by end of 2024. Two late-stage trials, ARTISTRY-7 for platinum-resistant ovarian cancer and ARTISTRY-6 for mucosal melanoma, expect data readouts in late Q1/early Q2 2025 and Q2 2025, respectively.

Mural Oncology (Nasdaq: MURA) has granted equity incentives to five new employees as inducement awards. The grants include 23,500 stock options with an exercise price of $3.46 per share and 12,500 restricted stock units. The stock options have a ten-year term and vest over four years, with 25% vesting after one year and 6.25% quarterly thereafter. The restricted stock units vest 25% annually over four years. These grants were made under the company's 2024 Inducement Stock Option and Incentive Plan in accordance with Nasdaq Rule 5635(c)(4).

Mural Oncology plc (Nasdaq: MURA) announced three upcoming poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 6-10, 2024, in Houston. The presentations will cover:

1. Tumor microenvironment pharmacodynamic data from the phase 1/2 ARTISTRY-3 study, evaluating less frequent dosing of nemvaleukin, Mural's engineered interleukin-2 (IL-2).

2. Preclinical efficacy and immune activity data for half-life extended IL-18 fusion proteins.

3. Modulation of IL-12p70 exposure and activity following sequential administration of tumor-targeted self-assembling split IL-12 subunits.

These presentations showcase Mural's progress in developing novel engineered cytokine therapies for cancer treatment, including their IL-2, IL-18, and IL-12 research programs.

Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, has announced the granting of inducement awards to three newly hired employees on October 1, 2024. The awards, granted under the company's 2024 Inducement Stock Option and Incentive Plan, include:

1. Non-statutory stock options to purchase 28,525 ordinary shares at an exercise price of $3.13 per share, equal to the closing price on October 1, 2024. These options have a ten-year term and vest over four years.

2. Restricted stock units for 14,975 ordinary shares, vesting over four years at 25% per year.

These grants are in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the employees' continued service with the company through applicable vesting dates.